TB-500 and Thymosin Beta-4: Why 1 in 80 Studies Is About the Compound You're Buying

Almost every claim made for TB-500 comes from research on a different molecule. Thymosin β4 is a 43-amino-acid protein your cells produce. TB-500 is a synthetic seven-amino-acid fragment of it, and the two are not interchangeable.

They are used interchangeably anyway — in vendor listings, forum posts and most published articles. This page separates them, inside the tissue repair and healing peptides category, and it is why this platform keeps TB-500 and thymosin β4 as separate compound pages rather than one page with an alias.

How much of the TB-500 research is actually about TB-500?

One study in eighty is about TB-500 itself. A 2026 scoping review included 80 studies, of which 70 were on thymosin β4 and exactly one was a direct TB-500 study — and that one was a metabolite-profiling and fibroblast-screening exercise, not a healing trial. The same review found no human interventional study of either compound in tendon, ligament, muscle, bone or cartilage, which is what nearly everyone buys TB-500 for.

The relationship between them is exact and checkable: residues 17–23 of thymosin β4 are L-K-K-T-E-T-Q — precisely TB-500. The fragment is formally Ac-Tβ4(17-23), the actin-binding motif lifted out of its parent protein.

That is a real chemical relationship, and it is the basis of a reasonable hypothesis: if the motif does the actin binding, maybe the motif does the work. But a motif excised from a 43-residue protein is not the protein, and the comparative studies that would establish equivalence have not been done. About one-fifth the length and one-fifth the mass is not a rounding difference.

What does thymosin β4 actually do?

Thymosin β4 is the major G-actin sequestering protein in mammalian cells. It binds monomeric actin, maintains a reserve available for rapid filament assembly, and through that governs cytoskeletal dynamics, cell migration, angiogenesis and wound repair. That is a whole-protein function. Prof. Allan Goldstein identified the compound, beginning thymosin work in 1964 at the Albert Einstein College of Medicine and continuing at George Washington University; his 2005 review remains the field's reference statement of the mechanism.

That review — "Thymosin β4: actin-sequestering protein moonlights to repair injured tissues" (Trends in Molecular Medicine, 2005) — is where the mechanism is stated most cleanly, and it describes what a 43-residue protein does, not what a seven-residue fragment of it does.

The landmark cardiac paper is Bock-Marquette et al., "Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair" — published in Nature in 2004, not Nature Medicine in 2003 as it is frequently miscited. It reported that Tβ4 promotes myocardial and endothelial cell migration, supports cardiomyocyte survival, and improves cardiac function after coronary ligation in animals.

TB-500, by contrast, has no discovery story. It has no founding publication and no research programme. It entered the research-chemical market rather than the literature, which is why the attribution problem exists at all — there was never a body of TB-500 work for the marketing to draw on.

What happened when thymosin β4 was tested in humans?

Thymosin β4 was tested properly in humans and mostly missed. A first-in-human Phase 1 study of recombinant human thymosin β4 (NL005) dosed 54 subjects single-dose at 0.05–25 µg/kg intravenously and 30 subjects across ten days, with no dose-limiting toxicities and no serious adverse events. RegeneRx then took a Tβ4-based eye drop into three Phase 3 dry-eye trials totalling more than 1,600 patients, which did not meet their pre-specified co-primary endpoints.

This is the part that gets left out, and it is the most informative evidence available.

The Phase 1 result (Journal of Cellular and Molecular Medicine, 2021) is clean — but clean for intravenous recombinant protein, at microgram-per-kilogram doses. It is not a safety result for a synthetic fragment injected subcutaneously in milligrams.

The efficacy record belongs to RegeneRx's RGN-259 programme:

More than 1,600 patients across three Phase 3 trials, and the parent protein did not clear its endpoints. That is the strongest signal anyone has about this molecule class in humans, and it points the opposite way from how TB-500 is marketed.

Which TB-500 claims survive the evidence?

None of the seven claims survives as a claim about TB-500. Every one fails on one of four grounds: no human interventional study exists in any musculoskeletal tissue, the supporting research belongs to thymosin β4 rather than TB-500, equivalence between the two has never been tested, or the figure has no locatable source. The safety data is real but comes from intravenous recombinant Tβ4, not subcutaneous TB-500 — wrong molecule, wrong route.

Two rows are marked "real" in the evidence column and still do not support a purchase, because what is real about them belongs to the 43-residue protein.

Did the July 2026 FDA vote make TB-500 legal?

No — the July 2026 vote did not change TB-500's legal status. At the Pharmacy Compounding Advisory Committee meeting of July 23–24, 2026, the committee voted 8–6 with one abstention to recommend TB-500 for the 503A bulks list — a recommendation that is advisory and non-binding. FDA must complete formal rulemaking before anything is added, projected for 2027 or later, and is not obliged to follow it. Nothing has been added, and TB-500's legal position today is unchanged.

The gap between "an advisory committee recommended" and "the FDA approved" is where most of the misreporting sits. A narrow committee margin is a signal about deliberation, not a change in status, and our FDA peptide regulation timeline tracks where each nomination actually stands.

Both compounds are prohibited at all times on the 2026 WADA Prohibited List under S2.3, Growth Factors and Growth Factor Modulators, which names "Thymosin-β4 and its derivatives e.g. TB-500." Neither is approved for human use by the FDA, EMA or TGA. Note that the WADA entry does the thing this article argues against — it treats TB-500 as a derivative of Tβ4 — and for prohibition purposes that is the correct call, because both are banned. For evidence purposes it is not.

What dose of TB-500 is supported by evidence?

No TB-500 dose is supported by published evidence, and no published study supports any community protocol. The only human pharmacokinetic data for this molecule class comes from intravenous recombinant thymosin β4 dosed in µg/kg, while community TB-500 protocols run to 2–4 mg per week subcutaneously during a loading phase — a different molecule, a different route, and roughly three orders of magnitude of difference in exposure. The widely repeated "5–7 day half-life" has no locatable source.

There is no evidence-based dosing regimen for TB-500, and this article does not present one. Stating a number here would create the impression of a protocol where none exists.

For reconstitution arithmetic only — working out volume per injection once a quantity has been chosen, which is a different question from what quantity to choose — use the BPC-157 + TB-500 calculator alongside the reconstitution calculator.

How do you verify which molecule is in the vial?

Mass spectrometry answers it, and TB-500's sourcing problem is unusually tractable because the two candidate molecules differ by 4,074 Da. Roughly 889 Da is TB-500; roughly 4,963 Da is thymosin β4. That is an enormous, unmistakable gap on a mass spectrometry trace — far easier to resolve than the 16 Da separating other commonly conflated pairs. Check the CAS number too: 885340-08-9 for TB-500, 77591-33-4 for thymosin β4.

Because the gap is so large, there is no technical excuse for a vendor not knowing which compound it is shipping. A CoA reporting only a purity percentage has told you nothing about identity — see mass spectrometry for peptides and how to read peptide lab test results. The compound-specific walkthrough is where to buy TB-500: 7 purity and identity checks, and the general framework is how to verify peptide quality before you buy.

Watch specifically for marketing that cites thymosin β4's cardiac or ophthalmic research while selling TB-500. That is the conflation operating commercially, and it is visible on the product page before any vial is opened.

Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026). Trust scores weight community reviews and independently verified HPLC purity equally, at 50% each, with no financial relationship influencing the ranking. Per-compound purity and test counts are read live from the Purity Index, independent results from the lab test database, per-milligram offers with shops-in-stock, median and lowest price from TB-500 price data, and vendor rankings from shops ranked by trust score. Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing. Independent laboratories are compared in third-party peptide testing labs.

How does TB-500 compare with the alternatives?

TB-500 has no human trials at all. Thymosin β4 has Phase 1 safety data and three Phase 3 ophthalmic trials that missed their endpoints. BPC-157 has broad rodent healing models and three uncontrolled human pilots totalling roughly 31 subjects. Progressive mechanical loading — physiotherapy — has a large controlled human evidence base, and for tendinopathy it is the comparator any peptide claim should be measured against.

The last row is not a joke. For tendinopathy — the most common reason people buy TB-500 — progressive loading has the strongest human evidence of anything in the table, and it is free of both the identity problem and the attribution problem.

The head-to-head with the usual stacking partner is in comparing BPC-157 and TB-500; the combined protocol in the BPC-157 + TB-500 stack guide and the Wolverine blend page. For the wider indication, see peptides for joint health, cartilage and tendon repair.

Why are community reports hard to read for TB-500?

TB-500 reports are hard to read because soft-tissue injuries are the worst possible setting for uncontrolled self-experimentation. Most of them improve with time, rest and loading regardless of what else is done, so a user who starts TB-500 during the natural recovery window of a tendon injury will observe improvement and reasonably attribute it to the compound. That is not a criticism of anyone's honesty — it is why controlled trials exist, and why their absence here matters so much.

The confound is strongest exactly where the compound is most used. A partial tendon injury treated with rest and graded loading follows a recovery curve that looks, from the inside, like a response to whatever was started at week two.

Reports sit in the Peptigrity forum and should be read as anecdote. They are useful for sourcing experience, delivery times, vial condition and adverse events — none of which requires a control group — and unreliable for efficacy, which does.

What trial would settle this?

The trial that would settle this tests TB-500 specifically, not thymosin β4, in one defined tendinopathy, randomised, double-blind and placebo-controlled, with subcutaneous dosing and PK sampling. Its endpoint is imaging plus a validated function score rather than subjective improvement, and its comparator is progressive loading rather than placebo, because beating placebo is not the useful question. Nothing resembling this exists or is registered.

Every row exists because a specific shortcut is currently being taken in its place.

Frequently Asked Questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a synthetic 7-amino-acid fragment (889 Da) corresponding to residues 17–23 of thymosin β4, a 43-amino-acid protein (4,963 Da). Studies of one are not automatically evidence for the other.

Has TB-500 been shown to heal tendons?

No. The 2026 scoping review found no human interventional study of either compound in tendon, ligament, muscle, bone or cartilage, and only one direct TB-500 study of any kind.

Does the July 2026 FDA vote make TB-500 legal?

No. The 8–6–1 recommendation is advisory. FDA has not completed rulemaking and is not required to follow it. TB-500 remains unapproved and prohibited in sport at all times.

Why do people say it has a 5–7 day half-life?

No source supports that figure. The only measured human pharmacokinetics is for intravenous recombinant thymosin β4 — a different molecule by a different route.

How do I know which molecule is in my vial?

Mass spectrometry. Roughly 889 Da is TB-500; roughly 4,963 Da is thymosin β4. The gap is large enough to be unmistakable.

What has the strongest human evidence for a tendon injury?

Progressive mechanical loading. It is the only entry in this article's comparison table with a large controlled human evidence base, and it is the standard of care any peptide claim would have to beat.

Thymosin β4 is a genuine protein with a real mechanism, decades of animal work, and a human trial record that is honest about its own limits — it was tested properly and mostly missed. TB-500 is a fragment of it that inherited the reputation without inheriting the research.

That inheritance is the whole story of this compound. Everything worth knowing about TB-500 depends on an assumption of equivalence that one study in eighty has even attempted to examine, and the test that would begin to settle it costs less than a vial.

Browse the tissue repair and healing peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For reconstitution and per-injection volume, use the BPC-157 + TB-500 calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.